Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking ...
Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer Patients with ...
Alternative splicing (AS) is a major contributor to transcriptome and proteome diversity. Evolutionary studies help to address questions that are fundamental to understanding this important process.
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51. The drug – formerly known as SRP-5051 – is ...
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations) Hybrid capture–based comprehensive genomic ...
Andamertinib showed promising efficacy in NSCLC patients with EGFR exon 20 mutations, achieving a 42.7% ORR in the 240-mg cohort. The study reported a median duration of response of 8.7 months and a ...
The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell lung cancer (NSCLC) associated with EGFR exon 20 insertions, the agency said.
Hereditary conditions cause those who suffer from them to live shorter lives with traumatic health issues. Because of this, researchers in the field of genetics are constantly exploring and developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results